Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Pruritus
- Focus Therapeutic Use
Most Recent Events
- 15 Jan 2025 Planned End Date changed from 1 May 2025 to 1 Jul 2025.
- 15 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 09 May 2024 Planned End Date changed from 1 Apr 2024 to 1 May 2025.